Get started
ABBVIE INC CEDEAR EA 10 REP 1 COM(USD)ABBVIE INC CEDEAR EA 10 REP 1 COM(USD)ABBVIE INC CEDEAR EA 10 REP 1 COM(USD)

ABBVIE INC CEDEAR EA 10 REP 1 COM(USD)

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

ABBVD chart


Full chart

Key facts today

JPMorgan lowered its price target on AbbVie Inc. (ABBV) to $200 from $210, keeping an overweight rating. Analysts report an average outperform rating, with price targets between $165 and $240.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪302.04 B‬ USD
Dividend yield (indicated)
3.28%
Price to earnings Ratio (TTM)
7.674
Basic EPS (TTM)
2.423 USD
Net income (FY)
‪1.76 B‬ USD
Revenue (FY)
‪19.78 B‬ USD
Shares float
—
Beta (1Y)
0.27

About AbbVie Inc.


Sector
Health Technology
CEO
Robert A. Michael
Headquarters
North Chicago
Website
abbvie.com
Founded
2011
ISIN
ARBCOM4603M9
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ABBVD news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ABBVD highest yielding bonds


A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
6.56%
Maturity date
Jun 15, 2044
A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
6.44%
Maturity date
Mar 15, 2045
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
6.31%
Maturity date
Oct 1, 2042
A
ACT4218882
Allergan Funding SCS 4.55% 15-MAR-2035
Yield to maturity
5.75%
Maturity date
Mar 15, 2035
ABBV4911706
AbbVie Inc. 3.2% 21-NOV-2029
Yield to maturity
5.70%
Maturity date
Nov 21, 2029
ABBV5759196
AbbVie Inc. 5.5% 15-MAR-2064
Yield to maturity
5.59%
Maturity date
Mar 15, 2064
ABBV5759195
AbbVie Inc. 5.4% 15-MAR-2054
Yield to maturity
5.49%
Maturity date
Mar 15, 2054
ABBV5068388
AbbVie Inc. 4.625% 01-OCT-2042
Yield to maturity
5.48%
Maturity date
Oct 1, 2042
ABBV4693583
AbbVie Inc. 4.875% 14-NOV-2048
Yield to maturity
5.46%
Maturity date
Nov 14, 2048
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044
Yield to maturity
5.42%
Maturity date
Jun 15, 2044
4ABB
ABBVIE 15/45
Yield to maturity
5.42%
Maturity date
May 14, 2045

Explore more bonds 

Sparks


Curated watchlists where ABBVD is featured.

See all sparks